GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (NAS:CTMX) » Definitions » PS Ratio
中文

CytomX Therapeutics (CytomX Therapeutics) PS Ratio : 1.18 (As of Apr. 24, 2024)


View and export this data going back to 2015. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CytomX Therapeutics's share price is $1.625. CytomX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.38. Hence, CytomX Therapeutics's PS Ratio for today is 1.18.

The historical rank and industry rank for CytomX Therapeutics's PS Ratio or its related term are showing as below:

CTMX' s PS Ratio Range Over the Past 10 Years
Min: 0.79   Med: 8.29   Max: 109.03
Current: 1.2

During the past 11 years, CytomX Therapeutics's highest PS Ratio was 109.03. The lowest was 0.79. And the median was 8.29.

CTMX's PS Ratio is ranked better than
90.62% of 992 companies
in the Biotechnology industry
Industry Median: 8.895 vs CTMX: 1.20

CytomX Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.33. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.38.

Warning Sign:

CytomX Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of CytomX Therapeutics was 69.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -0.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 27.80% per year.

During the past 11 years, CytomX Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 155.10% per year. The lowest was -25.90% per year. And the median was 11.75% per year.

Back to Basics: PS Ratio


CytomX Therapeutics PS Ratio Historical Data

The historical data trend for CytomX Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.01 4.42 7.44 1.98 1.13

CytomX Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 1.47 1.43 0.95 1.13

Competitive Comparison

For the Biotechnology subindustry, CytomX Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's PS Ratio falls into.



CytomX Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

CytomX Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.625/1.379
=1.18

CytomX Therapeutics's Share Price of today is $1.625.
CytomX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.38.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


CytomX Therapeutics  (NAS:CTMX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


CytomX Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytomX Therapeutics (CytomX Therapeutics) Business Description

Traded in Other Exchanges
Address
151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Executives
Marcia Belvin officer: SVP, Chief Scientific Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Christopher Ogden officer: SVP, Finance and Accounting C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Jeffrey B Landau officer: Chief Financial Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lloyd A Rowland officer: General Counsel AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Sean A. Mccarthy director, officer: President and CEO 343 OYSTER POINT BLVD., SUITE 100, SOUTH SAN FRANCISCO CA 94080
Yu-waye Chu officer: Chief Medical Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Amy C. Peterson officer: EVP, Chief Development Officer C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Carlos Campoy officer: Chief Financial Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Alison L. Hannah officer: Chief Medical Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Alan Ashworth director C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104